<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940627-0-00242</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4700 -->  <!-- PJG ITAG l=11 g=1 f=1 --> (i)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Fertility assessment/teratology.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The fertility  <!-- PJG 0012 frnewline --> assessment is an  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> in vivo  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> study designed to provide information on  <!-- PJG 0012 frnewline --> potential health hazards to the fetus arising from the mother's  <!-- PJG 0012 frnewline --> repeated exposure to vehicle/engine emissions before and during  <!-- PJG 0012 frnewline --> her pregnancy. By including a mating of test animals, the study  <!-- PJG 0012 frnewline --> provides preliminary data on the effects of repeated  <!-- PJG 0012 frnewline --> vehicle/engine emissions exposure on gonadal function,  <!-- PJG 0012 frnewline --> conception, and fertility. The fertility assessment/teratology  <!-- PJG 0012 frnewline --> guideline is found in &sect;79.63.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (ii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Micronucleus (MN) Assay.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The MN assay is an  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> in vivo <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->   <!-- PJG 0012 frnewline --> cytogenetic test which gives information on potential  <!-- PJG 0012 frnewline --> carcinogenic and/or mutagenic effects of exposure to vehicle/ <!-- PJG 0012 frnewline --> engine emissions. The MN assay detects damage to the chromosomes  <!-- PJG 0012 frnewline --> or mitotic apparatus of cells in the tissues of a test subject  <!-- PJG 0012 frnewline --> exposed repeatedly to vehicle/engine emissions. The assay is  <!-- PJG 0012 frnewline --> based on an increase in the frequency of micronucleated  <!-- PJG 0012 frnewline --> erythrocytes found in bone marrow from treated animals compared  <!-- PJG 0012 frnewline --> to that of control animals. The guideline for the MN assay is  <!-- PJG 0012 frnewline --> found in &sect;79.64.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (iii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Sister Chromatid Exchange (SCE) Assay.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The SCE assay  <!-- PJG 0012 frnewline --> is an  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> in vivo <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  analysis which gives information on potential  <!-- PJG 0012 frnewline --> mutagenic and/or carcinogenic effects of exposure to  <!-- PJG 0012 frnewline --> vehicle/engine emissions. The assay detects the ability of a  <!-- PJG 0012 frnewline --> chemical to enhance the exchange of DNA between two sister  <!-- PJG 0012 frnewline --> chromatids of a duplicating chromosome. This assay uses  <!-- PJG 0012 frnewline --> peripheral blood lymphocytes isolated from an exposed rodent test  <!-- PJG 0012 frnewline --> species and grown to confluence in cell culture. The guideline  <!-- PJG 0012 frnewline --> for the SCE assay is found in &sect;79.65.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (iv)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Neurotoxicity (NTX) measures.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> NTX measures include  <!-- PJG 0012 frnewline --> (A) histopathology of specified central and peripheral nervous  <!-- PJG 0012 frnewline --> system tissues taken from emission-exposed rodents, and (B) an  <!-- PJG 0012 frnewline --> assay of brain tissue levels of glial fibrillary acidic protein  <!-- PJG 0012 frnewline --> (GFAP), a major filament protein of astrocytes, from emission- <!-- PJG 0012 frnewline --> exposed rodents. The guidelines for the neurohistopathology and  <!-- PJG 0012 frnewline --> GFAP studies are found in &sect;79.66 and &sect;79.67, respectively.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Definitions.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> For the purposes of this section, the  <!-- PJG 0012 frnewline --> following definitions apply:  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> No-observed-adverse-effect-level (NOAEL)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> means the maximum  <!-- PJG 0012 frnewline --> concentration used in a test which produces no observed adverse  <!-- PJG 0012 frnewline --> effects. A NOAEL is expressed in terms of weight or volume of  <!-- PJG 0012 frnewline --> test substance given daily per unit volume of air (&mu;g/L or ppm).  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Subchronic inhalation toxicity  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> means the adverse effects  <!-- PJG 0012 frnewline --> occurring as a result of the continuous or repeated daily  <!-- PJG 0012 frnewline --> exposure of experimental animals to a chemical by inhalation for  <!-- PJG 0012 frnewline --> part (approximately 10 percent) of a life span.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (c)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Principle of the test method.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> As long as none of the  <!-- PJG 0012 frnewline --> requirements of any study are violated by the combination, one or  <!-- PJG 0012 frnewline --> more HEAs may be combined with the general toxicity study through  <!-- PJG 0012 frnewline --> concurrent exposures of their study populations and/or by sharing  <!-- PJG 0012 frnewline --> the analysis of the same animal subjects. Requirements  <!-- PJG 0012 frnewline --> duplicated in combined studies need not be repeated. Guidelines  <!-- PJG 0012 frnewline --> for combining HEAs with the general toxicity study are as  <!-- PJG 0012 frnewline --> follows.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Fertility assessment.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (i) The number of study animals in the test population is  <!-- PJG 0012 frnewline --> increased when the fertility assessment is run concurrently with  <!-- PJG 0012 frnewline --> the 90-day toxicity study. A minimum of 40 females per test  <!-- PJG 0012 frnewline --> group shall undergo vaginal lavage daily for two weeks before the  <!-- PJG 0012 frnewline --> start of the exposure period. The resulting wet smears are  <!-- PJG 0012 frnewline --> examined to cull those animals which are acyclic. Twenty-five  <!-- PJG 0012 frnewline --> females shall be randomly assigned to a for-breeding group with  <!-- PJG 0012 frnewline --> the balance of females assigned to a group for histopathologic  <!-- PJG 0012 frnewline --> examination.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (ii) All test groups are exposed over a period of 90 days  <!-- PJG 0012 frnewline --> to various concentrations of the test atmosphere for a minimum of  <!-- PJG 0012 frnewline --> six hours per day. After seven weeks of exposures, analysis of  <!-- PJG 0012 frnewline --> vaginal cell smears shall resume on a daily basis for the 25 for- <!-- PJG 0012 frnewline --> breeding females and shall continue for a period of four weeks or  <!-- PJG 0012 frnewline --> until each female in the group is confirmed pregnant. Following  <!-- PJG 0012 frnewline --> the ninth week of exposures, each for-breeding female is housed  <!-- PJG 0012 frnewline --> overnight with a single study male. Matings shall continue for  <!-- PJG 0012 frnewline --> as long as two weeks, or until pregnancy is confirmed (pregnancy  <!-- PJG 0012 frnewline --> day 0). Pregnant females are only exposed through day 15 of  <!-- PJG 0012 frnewline --> their pregnancy while daily exposures continue throughout the  <!-- PJG 0012 frnewline --> course of the study for non-pregnant females and study males.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (iii) On pregnancy day 20, pregnant females are sacrificed  <!-- PJG 0012 frnewline --> and their uteri are examined. Pregnancy status and fetal effects  <!-- PJG 0012 frnewline --> are recorded as described in &sect;79.63. At the end of the exposure  <!-- PJG 0012 frnewline --> period, all males and non-pregnant females are sacrificed and  <!-- PJG 0012 frnewline --> necropsied. Testes and epididymal tissue samples are taken from  <!-- PJG 0012 frnewline --> five perfusion-fixed test subjects and histopathological  <!-- PJG 0012 frnewline --> examinations are carried out on the remainder of the non-pregnant  <!-- PJG 0012 frnewline --> females and study males.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Carcinogenicity/mutagenicity <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=3 --> (C/M) assessment.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> When  <!-- PJG 0012 frnewline --> combined with the subchronic toxicity study, the main study  <!-- PJG 0012 frnewline --> population is used to perform both the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=3 --> in vivo <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  MN and SCE assays.  <!-- PJG 0012 frnewline --> Because of the constant turnover of the cells to be analyzed in  <!-- PJG 0012 frnewline --> these assays, a separate study population may be used for this  <!-- PJG 0012 frnewline --> assessment. A study population needs only to be exposed a  <!-- PJG 0012 frnewline --> minimum of four weeks. At exposure's end, ten animals per  <!-- PJG 0012 frnewline --> exposure and control groups are anaesthetized and heart punctures  <!-- PJG 0012 frnewline --> are performed on all members. After separating blood components,  <!-- PJG 0012 frnewline --> individual lymphocyte cell cultures are set up for SCE analysis.  <!-- PJG 0012 frnewline --> One femur from each study subject is also removed and the marrow  <!-- PJG 0012 frnewline --> extracted. The marrow is smeared onto a glass slide, and stained  <!-- PJG 0012 frnewline --> for analysis of micronuclei in erythrocytes.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Neurotoxicity (NTX) measures.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (i) When combined with this subchronic toxicity study, test  <!-- PJG 0012 frnewline --> animals designated for whole-body perfusion fixation/lung  <!-- PJG 0012 frnewline --> histology and exposed as part of the main animal population are  <!-- PJG 0012 frnewline --> used to perform the neurohistology portion of these measures.  <!-- PJG 0012 frnewline --> After the last exposure period, a minimum of ten animals from  <!-- PJG 0012 frnewline --> each exposure group shall be preserved  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> in situ <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  with fixative.  <!-- PJG 0012 frnewline --> Sections of brain, spinal cord, and proximal sciatic or tibial  <!-- PJG 0012 frnewline --> nerve are then cut, processed further in formalin, and mounted  <!-- PJG 0012 frnewline --> for viewing under a light microscope. Fibers from the sciatic or  <!-- PJG 0012 frnewline --> tibial nerve sample are teased apart for further analysis under  <!-- PJG 0012 frnewline --> the microscope.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (ii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> GFAP assay.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> After the last exposure period, a minimum  <!-- PJG 0012 frnewline --> of ten rodents from each exposure group shall be sacrificed, and  <!-- PJG 0012 frnewline --> their brains excised and divided into regions. The tissue  <!-- PJG 0012 frnewline --> samples are then applied to filter paper, washed with anti-GFAP  <!-- PJG 0012 frnewline --> antibody, and visualized with a radio-labelled Protein A. The  <!-- PJG 0012 frnewline --> filters are quantified for degree of immunoreactivity between the  <!-- PJG 0012 frnewline --> antibody and GFAP in the tissue samples. A non-radioactive ELISA  <!-- PJG 0012 frnewline --> format is also referenced in the GFAP guideline cited in  <!-- PJG 0012 frnewline --> paragraph (a)(2)(iv) of this section. Note: Because the GFAP  <!-- PJG 0012 frnewline --> assay requires fresh,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> i.e.,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> non-preserved, brain tissue, the  <!-- PJG 0012 frnewline --> number of test animals may need to be increased to provide an  <!-- PJG 0012 frnewline --> adequate number of test subjects to complete the histopathology  <!-- PJG 0012 frnewline --> requirements of both the GFAP and the general toxicity portion of  <!-- PJG 0012 frnewline --> the 90-day inhalation study.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            